查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594700

用於器官移植的免疫抑制劑市場：按藥物類別、移植類型、分銷管道分類 - 全球預測 2025-2030

Organ Transplant Immunosuppressant Drugs Market by Drug Class (Antibodies, Antiproliferative Agents, Calcineurin Inhibitors), Transplant Type (Heart, Kidney, Liver), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年器官移植免疫抑制劑市場價值為42.4億美元，預計2024年將達到45.2億美元，複合年成長率為7.09%，2030年將達到68.5億美元，預計將達到1000萬美元。

器官移植免疫抑制劑市場涉及用於預防移植後患者器官排斥的藥物。這些藥物對於器官移植的成功至關重要，因為它們會抑制攻擊新移植器官的免疫反應。用於腎臟、肝臟、心臟和肺移植，這是因為人體的先天免疫系統將移植器官識別為外敵。需求主要是由世界各地移植手術數量的增加、手術技術的進步以及術後護理的改善所推動的。然而，市場面臨藥品成本上漲、長期使用帶來的副作用以及影響藥物開發的嚴格監管要求等限制因素。另一個挑戰是確保在各種經濟狀況下，尤其是開發中國家，能夠公平地獲得這些關鍵藥物。儘管存在這些挑戰，但生物技術衍生的免疫抑制劑、個人化醫療方法以及數位健康整合以更好地病患監測等技術進步帶來了重大機會。公司應專注於研究開發副作用更少、療效更高的標靶治療。基因編輯和再生醫學的創新潛力為在不嚴重依賴全身免疫抑制的情況下提高移植成功率提供了前沿。專注於改進配方以提高患者的依從性，以及擴大與醫療機構的合作以提供全面的護理解決方案，可以開闢新的業務途徑。投資於患者教育宣傳活動還可以強調堅持免疫抑制療法和促進市場進入的重要性。總體而言，由於移植數量的增加和醫療進步，該市場擁有強勁的成長潛力，但策略性地應對監管和財務複雜性對於持續的業務成功至關重要。

主要市場統計
基準年[2023] 42.4億美元
預測年份 [2024] 45.2億美元
預測年份 [2030] 68.5億美元
複合年成長率（%） 7.09%

市場動態：器官移植市場快速發展的免疫抑制劑的主要市場洞察

供需的動態交互作用正在改變器官移植用免疫抑制劑的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 器官移植需求增加
    • 增加新產品的監管核准
    • 政府和非政府組織努力促進器官捐贈
  • 市場限制因素
    • 缺乏醫療專業人員專注於免疫抑制劑研究
  • 市場機會
    • 器官移植藥物開發的廣泛技術發展
    • 器官移植免疫抑制劑優勢報銷制度
  • 市場挑戰
    • 缺乏可行的器官

波特五力：駕馭器官移植免疫抑制劑市場的策略工具

波特的「五力」框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解器官移植免疫抑制劑市場的外部影響

外部宏觀環境因素在塑造器官移植免疫抑制劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解器官移植免疫抑制劑市場競爭狀況

器官移植免疫抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣器官移植免疫抑制劑市場供應商績效評估

FPNV定位矩陣是評估器官移植免疫抑制劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製器官移植免疫抑制劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對器官移植免疫抑制劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 器官移植需求增加
      • 新產品監理核准增加
      • 政府和非政府組織努力促進器官捐贈
    • 抑制因素
      • 缺乏專注於研究免疫抑制劑的醫療專業人員
    • 機會
      • 器官移植藥物開發的廣泛技術發展
      • 器官移植免疫抑制劑可享優惠回扣
    • 任務
      • 缺乏可行的器官
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章器官移植用免疫抑制劑市場（依藥物類別）

  • 抗體
  • 抗增殖劑
  • Calcineurin抑制劑
  • mTOR抑制劑
  • 類固醇

第7章依移植類型分類的器官移植免疫抑制劑市場

  • 心
  • 腎
  • 肝
  • 肺
  • 胰臟

第8章器官移植用免疫抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章：美洲器官移植用免疫抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太器官移植免疫抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲器官移植用免疫抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Accord Healthcare Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Midas Pharma GmbH
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SAS Alsachim by Shimadzu Group
  • Strides Pharma Global Pte Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-AD36CD897E17

The Organ Transplant Immunosuppressant Drugs Market was valued at USD 4.24 billion in 2023, expected to reach USD 4.52 billion in 2024, and is projected to grow at a CAGR of 7.09%, to USD 6.85 billion by 2030.

The organ transplant immunosuppressant drugs market pertains to pharmaceuticals used to prevent organ rejection in post-transplant patients. These drugs are crucial for the success of organ transplants, as they suppress the immune response that might attack the newly transplanted organ. Used across kidney, liver, heart, and lung transplants, their necessity stems from the body's natural immune mechanism that perceives the transplanted organ as a foreign invader. The demand is predominantly driven by the increasing number of transplant procedures globally, advancements in surgical techniques, and improved post-operative care. However, the market faces constraints including high drug costs, side effects associated with long-term use, and stringent regulatory requirements impacting drug development. Another challenge involves ensuring equitable access to these vital drugs across different economic settings, particularly in developing countries. Despite these challenges, there are significant opportunities arising from technological advancements like biotechnology-derived immunosuppressants, personalized medicine approaches, and the integration of digital health for better patient monitoring. Companies should focus on research into developing targeted therapies with fewer side effects and improved efficacy. The potential to innovate in gene editing and regenerative medicine presents a frontier for increasing transplant success rates without heavy dependence on generalized immunosuppression. Attention to improving drug formulations to enhance patient compliance, along with expanding collaborations with healthcare institutions for comprehensive care solutions, can open new business avenues. Investing in patient education campaigns can also drive market engagement by highlighting the importance of adherence to immunosuppressive regimens. Overall, while the market boasts robust growth potential due to rising transplant numbers and medical advancements, strategic navigation through its regulatory and financial complexities is essential for sustained business success.

KEY MARKET STATISTICS
Base Year [2023] USD 4.24 billion
Estimated Year [2024] USD 4.52 billion
Forecast Year [2030] USD 6.85 billion
CAGR (%) 7.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Organ Transplant Immunosuppressant Drugs Market

The Organ Transplant Immunosuppressant Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for organ transplantation
    • Growing approval for new products by the regulatory bodies
    • Government & NGO initiatives promoting organ donation
  • Market Restraints
    • Shortage of medical professionals focused on immunosuppressants research
  • Market Opportunities
    • Extensive technological developments in organ transplants drug development
    • Favorable reimbursement available for organ transplant immunosuppressant drugs
  • Market Challenges
    • Dearth of availability of viable organs

Porter's Five Forces: A Strategic Tool for Navigating the Organ Transplant Immunosuppressant Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Organ Transplant Immunosuppressant Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Organ Transplant Immunosuppressant Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Organ Transplant Immunosuppressant Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Organ Transplant Immunosuppressant Drugs Market

A detailed market share analysis in the Organ Transplant Immunosuppressant Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Organ Transplant Immunosuppressant Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Organ Transplant Immunosuppressant Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Organ Transplant Immunosuppressant Drugs Market

A strategic analysis of the Organ Transplant Immunosuppressant Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Organ Transplant Immunosuppressant Drugs Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Limited, Asahi Kasei Corporation, Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Lupin Limited, Midas Pharma GmbH, Neovii Pharmaceuticals AG, Novartis AG, Pfizer Inc., Sanofi S.A., SAS Alsachim by Shimadzu Group, Strides Pharma Global Pte Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Organ Transplant Immunosuppressant Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antibodies, Antiproliferative Agents, Calcineurin Inhibitors, mTOR Inhibitor, and Steroids.
  • Based on Transplant Type, market is studied across Heart, Kidney, Liver, Lung, and Pancreas.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for organ transplantation
      • 5.1.1.2. Growing approval for new products by the regulatory bodies
      • 5.1.1.3. Government & NGO initiatives promoting organ donation
    • 5.1.2. Restraints
      • 5.1.2.1. Shortage of medical professionals focused on immunosuppressants research
    • 5.1.3. Opportunities
      • 5.1.3.1. Extensive technological developments in organ transplants drug development
      • 5.1.3.2. Favorable reimbursement available for organ transplant immunosuppressant drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of availability of viable organs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Organ Transplant Immunosuppressant Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antibodies
  • 6.3. Antiproliferative Agents
  • 6.4. Calcineurin Inhibitors
  • 6.5. mTOR Inhibitor
  • 6.6. Steroids

7. Organ Transplant Immunosuppressant Drugs Market, by Transplant Type

  • 7.1. Introduction
  • 7.2. Heart
  • 7.3. Kidney
  • 7.4. Liver
  • 7.5. Lung
  • 7.6. Pancreas

8. Organ Transplant Immunosuppressant Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Organ Transplant Immunosuppressant Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Organ Transplant Immunosuppressant Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accord Healthcare Limited
  • 2. Asahi Kasei Corporation
  • 3. Astellas Pharma Inc.
  • 4. Dr. Reddy's Laboratories Ltd.
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. GlaxoSmithKline PLC
  • 7. Lupin Limited
  • 8. Midas Pharma GmbH
  • 9. Neovii Pharmaceuticals AG
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Sanofi S.A.
  • 13. SAS Alsachim by Shimadzu Group
  • 14. Strides Pharma Global Pte Ltd.
  • 15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY HEART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY LIVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2023